Beyond MGMT gene promoter methylation analysis, the subclassification of brain tumors in general and GBM in particular into DNA methylation‐based subgroups has spawned hopes to identify further treatment‐guiding predictive patterns [45]. This evidence concerns the gene MGMT and glioblastoma.